NASDAQ: NORDNordicus Partners Corp Stock
$3.68-1.23 (-25.05%)
Updated Nov 2, 2026
NORD Price
$3.68
Fair Value Price
N/A
Market Cap
$71.55M
52 Week Low
$1.48
52 Week High
$5.15
P/E
-13.14x
P/B
1.16x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.07M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$4M
Beta
-0.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NORD Overview
EKIMAS Corporation develops polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states. It offers polymers under the ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, HydroMed, and PolyBlend trade names. The company also manufactures specialty hydrophilic polyurethanes. It sells its products in the United States and internationally. The company was formerly known as AdvanSource Biomaterials Corporation and changed its name to EKIMAS Corporation in March 2020. EKIMAS Corporation was founded in 1993 and is headquartered in Wilmington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NORD's potential to beat the market
- NORD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NORD
RankedUnranked of 452
RankedUnranked of 452
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $961.26 | A | |
| $10.18 | A | |
| $361.27 | A |
Be the first to know about important NORD news, forecast changes, insider trades & much more!
NORD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NORD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NORD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NORD is good value based on its book value relative to its share price (1.16x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
NORD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NORD due diligence checks available for Premium users.
Valuation
NORD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.14x
Industry
17.34x
Market
44.91x
NORD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.16x
Industry
5.11x
NORD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NORD's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
NORD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$73.1M
Liabilities
$11.6M
Debt to equity
0.19
NORD's short-term liabilities ($1.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NORD's long-term liabilities ($9.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NORD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NORD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$159.8k
Investing
-$1.2k
Financing
$145.8k
NORD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NORD vs Biotech Stocks
Nordicus Partners Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.